Classification of patients having diffuse large b-cell lymphoma based upon gene expression
OwnerRonald Levy, Mark A. Wechser +4inventors
InventorsRonald Levy, Mark A. Wechser, Izidore S. Lossos, Robert J. Tibshirani, Ash A. Alizadeh, David Botstein
Life of this patent
Estimating the term…
Abstract
Methods and kits for classifying patients having diffuse large B-cell lymphoma (DLBCL) based upon expression of a plurality of genes are disclosed. Real-time quantitative RT-PCR can be used to measure expression values. Correlating expression values of the plurality of genes in a tumor sample from the patient to reference expression values obtained from DLBCL patients can stratify patients in the classification groups. The methods and kits can be used to predict overall patient survival.
Claims9
A kit for determining a survival probability of a patient diagnosed with Diffuse Large B-Cell Lymphoma (DLBCL), the kit comprising:
- reagents for measuring expression of a plurality of predictive genes in a sample from the patient diagnosed with DLBCL, the plurality of predictive genes including LMO2, BCL-6, FN1, CCND2, SCYA3, and BCL-2;
- and
- electronic media comprising software including a first algorithm for correlating a normalized expression data set from the plurality of predictive genes from the patient to expression data sets from the plurality of predictive genes obtained from DLBCL patients with known survival data, the plurality of predictive genes including LMO2, BCL-6, FN1, CCND2, SCYA3, and BCL-2;
- where a survival probability output is determined using the weighted predictor Z, according to the formula:
- Z=(A×LMO2)+(B×BCL6)+(C×FN1)+(D×CCND2)+(E×SCYA3)+(F×BCL2);
- wherein,
- A is −0.03, B is −0.2, C is −0.2, D is 0.03, E is 0.2, and F is 0.6;
- and
- LMO2, BCL6, FN1, CCND2, SCYA3, and BCL2 are log base 2 of normalized expression values for genes LMO2, BCL-6, FN1, CCND2, SCYA3, and BCL-2, respectively.
Dependencies are inferred from the claim text.